BMX 502
Alternative Names: BMX-502Latest Information Update: 21 Jan 2025
Price :
$50 *
At a glance
- Originator Biomunex Pharmaceuticals
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunologic cytotoxicity; T-lymphocyte subset stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours